Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors.
暂无分享，去创建一个
Z. Estrov | H. Kantarjian | J. Cortes | K. Patel | T. Kadia | P. Jain | F. Ravandi | G. Borthakur | E. Jabbour | N. Daver | S. O'brien | N. Pemmaraju | R. Luthra | K. Sasaki | C. Romo | G. González | R. Kanagal Shamanna | G. Gonzalez